ProQR Therapeutics BV Total Assets
ProQR Therapeutics BV total assets. Based on the latest financial reports, ProQR Therapeutics BV (PRQR) holds total assets worth $133.50 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ProQR Therapeutics BV (PRQR) total market value for the company's overall valuation and market capitalisation.
Total Assets of ProQR Therapeutics BV (2012–2025)
Total assets of ProQR Therapeutics BV from 2012 to 2025. This chart illustrates how ProQR Therapeutics BV's total assets have evolved over time, based on quarterly financial data. See ProQR Therapeutics BV share price for real-time trading data and today's change.
ProQR Therapeutics BV - Asset Composition Analysis
ProQR Therapeutics BV Total Assets Breakdown (December 2025)
ProQR Therapeutics BV total assets breakdown as of December 2025. ProQR Therapeutics BV's total assets of $133.50 Million consist of 88.8% current assets and 11.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.0% |
| Accounts Receivable | $5.97 Million | 4.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how ProQR Therapeutics BV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ProQR Therapeutics BV current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProQR Therapeutics BV's current assets represent 88.8% of total assets in 2025, an increase from 88.5% in 2012.
- Cash Position: Cash and equivalents constituted 82.0% of total assets in 2025, up from 73.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
ProQR Therapeutics BV Competitors by Total Assets
Key competitors of ProQR Therapeutics BV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
ProQR Therapeutics BV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.49 | 3.76 | 5.10 |
| Quick Ratio | 3.49 | 3.76 | 5.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $86.72 Million | $107.04 Million | $165.00 Million |
ProQR Therapeutics BV - Advanced Valuation Insights
This section examines the relationship between ProQR Therapeutics BV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.63 |
| Latest Market Cap to Assets Ratio | 1.50 |
| Asset Growth Rate (YoY) | -23.9% |
| Total Assets | $132.43 Million |
| Market Capitalization | $198.98 Million USD |
Valuation Analysis
Above Book Valuation: The market values ProQR Therapeutics BV's assets above their book value (1.50x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: ProQR Therapeutics BV's assets decreased by 23.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ProQR Therapeutics BV (2012–2025)
The table below shows the annual total assets of ProQR Therapeutics BV from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $132.43 Million | -23.86% |
| 2024-12-31 | $173.92 Million | +14.19% |
| 2023-12-31 | $152.31 Million | -16.70% |
| 2022-12-31 | $182.84 Million | -23.28% |
| 2021-12-31 | $238.33 Million | +97.30% |
| 2020-12-31 | $120.80 Million | -8.44% |
| 2019-12-31 | $131.93 Million | +19.69% |
| 2018-12-31 | $110.23 Million | +72.87% |
| 2017-12-31 | $63.77 Million | -7.76% |
| 2016-12-31 | $69.13 Million | -36.43% |
| 2015-12-31 | $108.75 Million | -22.02% |
| 2014-12-31 | $139.45 Million | +2146.99% |
| 2013-12-31 | $6.21 Million | +1292.73% |
| 2012-12-31 | $445.62K | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more